About-cancer/treatment/drugs/eltrombopagolamine/zh

Eltrombopag Olamine

本页包含有关Eltrombopag olamine的简要信息，以及一些链接，这些链接指向有关该药物的用途，研究结果和正在进行的临床试验的更多信息。

美国品牌名称

Promacta

FDA批准

是

该药物的FDA标签信息可从DailyMed获得。

用于癌症

Eltrombopag olamine被批准用于治疗：

• 血小板减少症 （低血小板水平）。 它用于成人和1岁或1岁以上的慢性免疫性血小板减少症（ITP）的儿童。 ITP是血小板被免疫系统破坏的疾病。 Eltrombopag olamine用于某些ITP患者，但其他治疗未见好转。

Eltrombopag olamine也正在研究其他疾病和类型的癌症中。

关于Eltrombopag Olamine的更多信息

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Eltrombopag Olamine - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,

• what this drug is used for and how it is used,

• what you should tell your doctor before using this drug,

• what you should know about this drug before using it,

• other drugs that may interact with this drug, and

• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials Accepting Patients

Find Clinical Trials for Eltrombopag Olamine - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.